Spruce Biosciences Inc. (SPRB): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPRB Stock Price Chart Interactive Chart >
SPRB Price/Volume Stats
| Current price | $2.95 | 52-week high | $3.38 |
| Prev. close | $2.72 | 52-week low | $0.95 |
| Day low | $2.72 | Volume | 104,461 |
| Day high | $3.09 | Avg. volume | 4,340,723 |
| 50-day MA | $1.63 | Dividend yield | N/A |
| 200-day MA | $1.63 | Market Cap | 69.50M |
Spruce Biosciences Inc. (SPRB) Company Bio
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.
Latest SPRB News From Around the Web
Below are the latest news stories about SPRUCE BIOSCIENCES INC that investors may wish to consider to help them evaluate SPRB as an investment opportunity.
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023SOUTH SAN FRANCISCO, Calif., January 09, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayThe final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! |
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in JapanSpruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and |
Spruce Biosciences Surges On Tie-up With Kaken Pharma To Develop Investigational Drug TildacerfontShares of Spruce Biosciences, Inc. (SPRB) are rising more than 100% Friday morning after the company announced partnership with Japan''s Kaken Pharmaceutical to develop Spruce''s investigational drug, tildacerfont, for the treatment of congenial adrenal hyperplasia (CAH). |
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday''s Mid-Day SessionGainers Swvl Holdings Corp. (NASDAQ: SWVL ) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. Spruce Biosciences, Inc. (NASDAQ: SPRB ) shares jumped 100.8% to $2.51. Spruce Biosciences and Kaken Pharmaceutical reported an exclusive licensing agreement to develop and commercialize Tildacerfont for CAH in Japan. MedAvail Holdings, Inc. (NASDAQ: MDVL ) gained 54% to $0.4745. MedAvail Holdings, during November, posted a Q3 loss of $0.15 per share. CytomX Therapeutics, Inc. (NASDAQ: CTMX ) climbed 46.4% to $2.6198. CytomX and Moderna reported a strategic research collaboration for mRNA-based conditionally activated therapeutics. Zomedica Corp. (NYSE: ZOM ) gained 38% to $0.2649 after Dawson James initiated coverage on the stock with a Buy rating ... |
SPRB Price Returns
| 1-mo | 168.82% |
| 3-mo | 173.15% |
| 6-mo | 43.90% |
| 1-year | 16.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 168.82% |
| 2022 | -75.39% |
| 2021 | -81.65% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...